Home » Newsletters » BioWorld Science

BioWorld Science

April 13, 2018

View Archived Issues

CTA approval for ARGX-112 triggers milestone payment to Argenx

ImmunoCellular Therapeutics achieves milestone in Stem-to-T-Cell program

Phase I trial of TQB-2450 approved and initiated in China

RubrYc Therapeutics closes series A financing

Adynxx presents promising phase II data from ADYX-004 study of brivoligide

Novel mutation in SMARCE1 gene discovered in OAFNS

Humanetics obtains NIAID grant to support development of BIO-300 as a medical countermeasure

Beijing Tiancheng Pharma divulges new FGFR inhibitors

BMS and Harvard enter fibrosis research collaboration

University of Ottawa, Lcb Pharma patent nucleoside and nucleotide analogues

Patient recruitment ongoing in phase I study of BIIB-095

Novel dopamine beta-hydroxylase inhibitors identified at BIAL-Portela & Ca.

Dinutuximab plus irinotecan well tolerated in part 1 of phase II/III small cell lung cancer study

Emergent BioSolutions completes MRP for BioThrax in five E.U. countries

Deerfield leads investment in Sollis Therapeutics

Galapagos announces plans for phase III program of GLPG-1690 in IPF

New PIEZO1 gene mutations associated with nonimmune hydrops fetalis

STK25 identified as a therapeutic target for NAFLD

FDA finalizes guidance on NGS-based tests

Phase I/II study of DNA vaccine for hypertension begins in Australia

GSK to transfer rare disease gene therapy portfolio to Orchard Therapeutics

PCSK7, a potential therapeutic target for metabolic disorders

FDA approves use of IDx-DR to detect diabetic retinopathy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...